by Richard Daverman, PhD
April 3, 2013 -- Hangzhou Nurotron Biotechnology has developed a less expensive cochlear implant, a medical device that allows severely deaf people to hear again. In China, the company offers a $16,000 implant, half the cost of the market-leading Australian import, a $32,000 device from Cochlear Ltd. Nurotron is headquartered in Hangzhou, where it also has a manufacturing facility. But its R&D operation is in Irvine, California, close to the home of its founder, Fan-Gang Zeng, PhD, the Director of the Center for Hearing Research at University of California at Irvine. More details....
Stock Symbol: (ASX: COH)
